Altrova Health Announces Launch Of O-Spray Product Line And Provides Corporate Update

May 05, 2026 7:04 AM EDT | Source: Altrova Health Inc.

Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: SSPLF) (FSE: QM4) (" Altrova Health " or the " Company ") today announced the introduction of O-SprayTM, a needle-free sublingual oral spray dosage format designed as an alternative to self-injection, pill, and syringe-based administration. O-Spray is positioned across current and future therapeutic areas including weight management, erectile dysfunction, menopause-related care, and other indications where an oral spray format may be appropriate.

Market Context

The global GLP-1 receptor agonist market was valued at approximately USD 53.5 billion in 2024 and is projected to reach approximately USD 315 billion by 2035 at a CAGR of 17.5%.¹ In Canada, the market generated approximately USD 2.1 billion in 2025 and is projected to reach USD 6.6 billion by 2033 at a CAGR of 14.2%.² Despite this scale, injectable administration accounted for approximately 83% of global GLP-1 market share by route of administration in 2024, while the oral and alternative delivery segment is projected to be the fastest-growing category going forward.³ O-Spray dosage formats supports prescription-based sublingual alternatives within this context.

About O-Spray

O-Spray utilizes an airless metered-dose pump that delivers a precise, consistent dose with each actuation. The format requires no needles, preparation, refrigeration, or mixing. Administration involves a quick spray under the tongue, a ten-minute absorption window, and no further steps.

Key format features include:

Airless pump technology maintaining formulation stability and consistent dosing

Compact, discreet design suitable for daily carry; shelf-stable at room temperature

The dosage format is a documented consideration in patient engagement. A Canadian study published in Vaccine found that approximately 24% of adults report a fear of needles, and a 2022 global survey of 2,098 adults published in PLOS One found that 94.1% of needle-phobic respondents identified non-invasive device alternatives as their preferred mitigation approach.^4,5

O-Spray is designed to support healthcare-professional discussions for patients where administration method is a relevant factor in their care decisions. For more information, visit .

Management Commentary

"The introduction of O-Spray represents an important step in Altrova Health's strategy to deliver accessible delivery formats across high-demand therapeutic categories," said Geoff Benic, Chief Executive Officer of Altrova Health "We believe the combination of a needle-free sublingual format with a metered-dose system engineered for precision and ease of use addresses a real and underserved dimension of patient preference."

"O-Spray reflects our commitment to building a health platform that meets patients where they are," said Raf Souccar, Chairman of the Board of Altrova Health "Administration format meaningfully affects how people engage with their treatment. By offering a needle-free, discreet alternative, we believe O-Spray can support stronger patient-provider conversations and broaden access to care for individuals who may otherwise delay or avoid treatment."

Update on Healthy Sprays Agreement

The Company also wishes to advise that it has mutually agreed with Healthy Sprays LLC (" Healthy Sprays ") to terminate the Exclusive Territory License and Commercial Agreement dated November 21, 2025 (the " Healthy Sprays Agreement "), which was previously announced by the Company on November 24, 2025. Pursuant to a settlement agreement and mutual release entered into between the parties, the Healthy Sprays Agreement has been rescinded in its entirety and the parties have exchanged full and final mutual releases. No additional payments were made by either party in connection with the termination. The Company has no further commercial obligations to Healthy Sprays, and Healthy Sprays has no further commercial obligations to the Company.

About Altrova Health Inc.

Altrova Health Inc. (CSE: ROVA) (OTCQB: SSPLF) (FSE: QM4) is a Canadian public company building a growing portfolio of health solutions across detection, protection, treatment, and wellness. The Company's current product portfolio includes exclusive Canadian distribution rights for the NIRLAB SA (" NIRLAB ") NIRLIGHT drug analysis device, the ToxiShield fentanyl and drink-spiking detection product line, and the O-Spray product line.

For more information, please visit .

On behalf of the Board of Directors of Altrova Health Inc.

"Geoff Benic"
Geoff Benic, CEO

MENAFN05052026004218003983ID1111070143